cystic
fibrosi
cf
characteris
respiratori
pancreat
defici
stem
loss
fulli
function
cftr
cf
transmembran
conduct
regul
membran
epitheli
cell
current
treatment
modal
aim
delay
deterior
lung
function
mostli
respons
rel
short
life
expect
cf
suffer
howev
none
far
success
dealt
underli
molecular
defect
novel
pharmacolog
approach
amelior
lack
activ
cftr
respiratori
epitheli
cell
begin
address
pathophysiolog
defect
caus
cftr
mutat
howev
cftr
gene
replac
gene
therapi
remain
like
option
address
basic
defect
includ
ion
transport
inflammatori
function
cftr
chapter
review
latest
preclin
clinic
advanc
pharmacotherapi
gene
therapi
cf
lung
diseas
cystic
fibrosi
cf
common
lethal
autosom
recess
disord
among
caucasian
caus
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
identifi
posit
clone
encod
chlorid
cl
channel
express
epithelia
mani
tissu
gene
encod
singl
polypeptid
chain
amino
acid
predict
molecular
weight
around
kda
cftr
protein
embed
apic
membran
epitheli
cell
made
distinct
structur
domain
includ
two
membran
span
domain
msd
two
nucleotid
bind
domain
nbd
contain
conserv
motif
atp
bind
hydrolysi
regulatori
domain
r
cftr
protein
member
abc
famili
protein
normal
function
campactiv
clchannel
shown
interact
ion
channel
transport
amiloridesensit
epitheli
sodium
channel
enac
recent
review
berdiev
et
al
outwardli
rectifi
chlorid
channel
orcc
review
kunzelmann
cystic
fibrosi
mutat
databas
http
wwwgenetsickkidsonca
current
list
mutat
locat
throughout
gene
affect
domain
protein
common
mutat
found
diseas
allel
caus
delet
three
consecut
base
pair
result
loss
phenylalanin
mutat
cftr
gene
group
five
class
base
effect
cftr
protein
express
andor
function
class
iiii
mutat
commonli
caus
sever
diseas
phenotyp
class
iv
v
mutat
tend
associ
milder
diseas
although
systemat
lung
diseas
highli
variabl
even
within
ident
genet
background
mutat
cftr
disrupt
transport
epithelium
sever
tissu
result
product
abnorm
thick
sticki
mucu
main
caus
morbid
cf
lung
diseas
deterior
lung
function
pulmonari
failur
caus
death
major
patient
product
thick
sticki
mucu
lumen
lung
imped
mucociliari
clearanc
consequ
chronic
inflamm
ation
recurr
bacteri
infect
typic
pseudomona
aeruginosa
burkholderia
cepacia
complex
selfperpetu
cycl
lead
progress
destruct
lung
tissu
sever
case
p
aeruginosa
form
antibiot
resist
biofilm
lumen
airway
presenc
correl
declin
lung
function
airway
epitheli
cell
aec
cover
air
surfac
liquid
asl
made
mucu
layer
trap
potenti
harm
particul
matter
inhal
periciliari
liquid
pcl
layer
pcl
provid
less
viscou
layer
cilia
beat
remov
mucu
contain
trap
particl
airway
mucociliari
clearanc
pcl
also
act
lubric
mucu
layer
mucin
tether
cell
surfac
facilit
cough
clearanc
final
pcl
contain
antimicrobi
peptid
protein
eg
defensin
lysozym
lactoferrin
antimicrobi
surfact
protein
fight
pathogen
cf
process
disrupt
caus
dysregul
liquid
movement
lung
infect
inflamm
low
volum
hypothesi
also
know
isoton
volum
transportmucu
clearanc
theori
implic
reduc
asl
volum
initi
event
cf
lung
patholog
airway
epithelium
thought
regul
asl
volum
height
pcl
layer
approxim
extend
cilia
cell
surfac
epithelium
around
allow
beat
effici
cf
airway
asl
volum
henc
pcl
height
decreas
make
mucu
layer
sticki
harder
move
result
flatten
cilia
prevent
beat
caus
mucu
adher
cell
togeth
event
lead
defect
mucociliari
clearanc
initi
chronic
cycl
infect
inflamm
characterist
cf
lung
review
boucher
signific
amount
evid
support
low
volum
hypothesi
primari
human
cell
cultur
mous
model
recent
acceler
na
absorpt
lead
decreas
pcl
height
reduc
mucociliari
clearanc
demonstr
vivo
overexpress
mous
review
mall
primari
airliquid
interfac
ali
cultur
cf
patient
recent
avail
overexpress
mous
lung
patholog
close
mirror
cf
patient
provid
power
tool
understand
link
cftr
defici
complex
pathophysiolog
cf
exampl
steril
inflamm
also
observ
mice
support
hypothesi
inflamm
occur
independ
infect
pharmacolog
process
restor
effect
asl
height
mucociliari
clearanc
cf
patient
could
target
upregul
cftr
activ
modifi
altern
channel
enac
calciumactiv
clchannel
cacc
rehydr
asl
hyperosmot
agent
inhal
mannitol
hyperton
salin
current
approach
pharmacolog
correct
cftr
includ
drug
increas
level
cftr
protein
synthesis
cftr
corrector
increas
traffick
er
cftr
potenti
correct
gate
defect
cftr
membran
fig
sever
strategi
increas
amount
cftr
cell
surfac
investig
includ
increas
overal
transcript
level
butyr
sodium
although
neither
impact
clinic
trial
sever
drug
promot
readthrough
nonsens
stop
codon
shown
produc
fulllength
cftr
includ
aminoglycosid
antibiot
eg
gentamicin
recent
develop
latter
appear
capabl
improv
electrophysiolog
featur
nasal
epithelium
sever
clinic
relev
outcom
measur
fvc
circul
neutrophil
interestingli
report
drug
may
effect
case
prematur
stop
codon
due
exon
skip
remov
earli
stop
codon
matur
mrna
enhanc
traffick
cftr
use
chemic
chaperon
increas
cftr
level
membran
preclin
studi
recent
effort
identifi
cftrspecif
corrector
involv
highthroughput
screen
inhibitor
sildenafil
show
promi
sg
sumnerjon
et
al
figur
schemat
represent
site
action
pharmacolog
correct
cftr
defici
pharmacolog
drug
investig
correct
cftr
defici
may
act
increas
level
mrna
enhanc
transcript
translat
transcript
translat
activ
correct
traffick
defect
endoplasm
reticulum
cftr
corrector
increas
activ
cftr
membran
cftr
potenti
regul
ion
channel
epitheli
na
channel
enac
enac
inhibitor
ca
activ
cl
channel
cacc
site
action
drug
airway
epitheli
cell
indic
white
arrow
rel
cftr
biosynthesi
atpdepend
channel
activ
rel
pathway
activ
inhibit
cacc
enac
respect
ing
correct
cf
defect
vitro
current
phase
iii
clinic
studi
expect
conclud
much
potent
analogu
sildenafil
earli
stage
develop
differ
corrector
miglustat
function
inhibit
thu
prevent
rapid
degrad
er
shown
promis
multipl
preclin
studi
miglustat
phase
ii
trial
actelion
cftr
corrector
discov
collabor
programm
vertex
cystic
fibrosi
foundat
therapeut
inc
recent
enter
phase
ii
safetyefficaci
studi
result
studi
eagerli
await
potenti
drug
therapi
base
increas
activ
cftr
increas
level
cyclic
nucleotid
cell
use
phosphodiesteras
pde
inhibitor
milrinon
direct
activ
curcumin
genistein
cpx
promis
advanc
involv
vertex
compound
drug
increas
open
probabl
clconduct
cftr
complet
phase
iia
trial
enter
fda
registr
programm
upregul
cacc
ca
activ
clchannel
denufosol
lancovutid
recent
demonstr
safe
toler
way
induc
cltransport
via
noncftr
channel
evalu
efficaci
cf
patient
drug
ongo
altern
enac
activ
could
inhibit
order
decreas
elev
na
absorpt
seen
cf
airway
parion
compound
recent
improv
enac
inhibitor
amilorid
alreadi
enter
clinic
trial
includ
one
cf
current
way
inhibit
serin
proteas
prevent
activ
enac
candid
yet
proceed
beyond
preclin
studi
recent
smallmolecul
inhibitor
proteas
involv
enac
regul
camostat
test
success
sheep
aerosol
studi
improv
mucociliari
clear
anc
sever
hour
administr
partial
correct
toward
normal
na
transport
defect
nose
cf
patient
report
confirm
promis
candid
evalu
clinic
cf
lung
diseas
although
data
encourag
major
new
drug
treatment
modest
abil
correct
cf
defect
act
cftr
mutat
even
success
may
benefit
small
proport
patient
depend
genotyp
also
like
pharmacolog
approach
discuss
could
requir
use
combin
optim
correct
cf
ion
transport
defect
exampl
corrector
potenti
simultan
adjust
enac
activ
third
compon
may
limit
use
clinic
certainli
take
time
evalu
trial
basic
concept
gene
therapi
involv
introduc
gene
target
cell
prevent
slow
progress
diseas
cf
good
candid
technolog
primarili
caus
mutat
singl
gene
normal
copi
could
deliv
patient
via
topic
deliveri
lung
without
invas
techniqu
surgeri
moreov
gene
complement
approach
would
directli
target
caus
diseas
could
correct
mani
aspect
complex
lung
patholog
singl
therapi
treat
underli
defect
could
greatli
reduc
high
therapeut
burden
cf
patient
current
endur
addit
one
therapi
might
suitabl
treat
subject
wide
varieti
mutat
mean
singl
treatment
strategi
could
relev
patient
proof
principl
viral
nonvir
cftr
gene
transfer
quickli
establish
cf
patient
date
trial
complet
involv
approxim
cf
individu
see
griesenbach
two
dna
viral
vector
adenoviru
ad
adenoassoci
viru
aav
evalu
cf
gene
therapi
clinic
trial
trial
ad
vector
disappoint
compar
preclin
studi
term
persist
gene
express
level
gene
transfer
human
airway
gutless
adenoviru
also
refer
helperdepend
ad
viral
genom
remov
apart
invert
termin
repeat
itr
viral
packag
sequenc
shown
extend
durat
transgen
express
reduc
toxic
immunogen
mice
compar
previou
gener
ad
readministr
remain
problemat
due
presenc
viral
capsid
protein
altern
viral
vector
investig
cf
clinic
studi
nonpathogen
aav
phase
ii
clinic
trial
administ
singl
dose
express
cftr
nose
lung
cf
patient
deem
safe
result
consist
detect
vectorderiv
dna
day
week
deliveri
cftr
mrna
rare
detect
trial
although
two
studi
report
transient
correct
clconduct
defect
nose
week
deliveri
treatment
result
detect
clinic
benefit
lung
function
neutralis
antibodi
vector
detect
serum
two
trial
readminist
viru
perform
similar
lack
clinic
benefit
disappoint
comparison
preclin
studi
mice
particular
partli
attribut
pauciti
receptor
apic
membran
human
cell
thu
altern
serotyp
potenti
improv
tropism
airway
epitheli
cell
investig
appear
transduc
airway
epitheli
cell
effici
transduct
effici
recent
report
mous
airway
use
hybrid
chicken
globin
promoterintron
human
cmv
immedi
earli
enhanc
cag
lack
effici
repeat
administr
clinic
studi
keep
preclin
studi
show
inabl
readminist
airway
anim
unless
genotyp
switch
readministr
interestingli
demonstr
serotyp
viru
could
readminist
success
murin
airway
month
initi
dose
addit
difficulti
tropism
immun
respons
util
aav
cf
hamper
limit
packag
capac
raav
vector
kb
advanc
field
includ
develop
minicftr
gene
may
packag
effici
includ
safeti
studi
nonhuman
primat
function
studi
mice
discoveri
could
fact
packag
larg
genom
kb
reason
yield
compar
raav
pseudotyp
togeth
evid
suggest
aav
vector
may
abl
target
progenitor
cell
mous
lung
thu
avoid
need
repeat
administr
work
continu
make
increment
improv
murin
parainfluenza
viru
type
sendai
viru
sev
human
respiratori
syncyti
viru
rsv
human
parainfluenza
viru
type
neg
strand
rna
virus
whose
life
cycl
complet
cytoplasm
shown
transfect
aec
effici
via
apic
membran
express
function
cftr
channel
vivo
elicit
immun
respons
current
inhibit
repeat
administr
although
virus
may
use
acut
diseas
requir
transient
gene
express
context
cf
use
restrict
preclin
proof
principl
studi
immunolog
barrier
repeat
administr
resolv
lentivirus
retrovirus
transduc
nondivid
cell
includ
termin
differenti
aec
viral
dsdna
genom
stabli
integr
genom
transduc
cell
rna
revers
transcrib
express
like
last
lifetim
cell
approxim
month
aec
vsvgpseudotyp
hivderiv
lentiviru
carri
cftr
gene
transient
partial
correct
cldefect
cf
knockout
mous
nose
day
although
pretreat
tight
junction
open
lysophosphatidylcholin
necessari
attempt
improv
tropism
lentiviru
pseudotyp
envelop
glycoprotein
filovirus
ebola
marburg
baculoviru
spike
envelop
glycoprotein
sar
viru
f
hn
protein
sev
latter
vector
fhnsiv
abl
transduc
polaris
epitheli
cell
apic
basolater
side
importantli
murin
aec
vivo
without
need
precondit
gene
express
vivo
persist
least
month
ie
lifetim
aec
consist
gene
express
month
mous
nose
virus
import
research
address
challeng
multipl
repeat
administr
without
loss
efficaci
find
way
target
stem
cell
popul
airway
treat
chronic
aspect
cf
lung
diseas
need
effect
longterm
repeat
administr
treat
cf
lung
diseas
led
investig
nonvir
vector
take
form
circular
plasmid
dna
pdna
deliv
cell
nake
pdna
diluent
pb
salin
water
complex
agent
lipid
polyc
protect
extracellular
degrad
aid
cellular
entri
rel
lack
effici
compar
viral
vector
counterbalanc
reduc
safeti
concern
regard
integr
flexibl
easier
product
methodolog
extend
storag
unlimit
packag
capac
nonvir
phase
clinic
trial
deliv
pdna
express
cftr
began
mid
varieti
cation
liposom
formul
deliv
nose
andor
lung
cf
patient
gener
gene
transfer
well
toler
evid
cftr
gene
transfer
measur
vectorspecif
mrna
cftrmediat
chlorid
transport
establish
studi
review
roseneck
et
al
one
side
effect
lipid
formul
transient
mild
flulik
symptom
report
ruiz
alton
lung
trial
dope
dmpepegpdna
inflamm
may
relat
stimul
tolllik
receptor
bacteriallyderiv
cpg
dinucleotid
formu
sg
sumnerjon
et
al
lation
bid
reduc
respons
uk
cfgt
consortium
gener
cpgfree
pdna
cf
clinic
trial
way
delet
cpg
motif
one
latest
aspect
plasmid
develop
programm
field
cf
gene
therapi
common
featur
previou
trial
transient
natur
correct
measur
persist
express
improv
preclin
studi
swap
viral
promot
cmv
cytomegaloviru
human
promot
includ
ubc
polyubiquitin
c
elong
factor
similarli
specif
improv
mice
use
human
cytokeratin
promot
direct
epitheli
cellspecif
transgen
express
mice
clinic
trial
data
confirm
whether
modif
dna
construct
improv
durat
toler
gene
transfer
nose
lung
cf
patient
tabl
summaris
featur
recent
nonvir
vector
develop
context
airway
gene
therapi
particular
polyc
shown
promis
lung
gene
therapi
polyethylenimin
pei
commonli
use
form
kda
branch
pei
kda
linear
pei
although
use
lung
gene
therapi
clinic
trial
date
peipdna
complex
led
success
gene
deliveri
clinic
relev
model
aerosol
gene
deliveri
work
toward
improv
formul
concentr
particl
shown
promis
result
murin
airway
studi
follow
comparison
differ
nonvir
formul
concentr
kda
pei
select
wave
product
uk
cfgt
consortium
addit
improv
may
also
come
field
integras
recent
demonstr
mice
treat
integraseencod
report
construct
complex
pei
express
report
protein
longer
treat
nonintegraseencod
construct
cation
polym
use
clinic
trial
cf
gene
therapi
date
compact
dna
nanoparticl
consist
singl
molecul
pdna
compact
lysin
polym
coval
link
polyethylen
glycol
peg
advantag
gene
transfer
agent
identif
receptor
cell
uptak
nucleolin
nuclear
transloc
bypass
endosom
pathway
phase
studi
result
detect
vectorderiv
dna
day
dose
nasal
epithelium
cf
patient
partial
complet
correct
cltransport
defect
patient
clear
genotyp
cf
patient
entir
predict
cours
diseas
particularli
rate
declin
lung
function
number
sg
sumnerjon
et
al
i
attempt
identifi
modifi
gene
differ
aspect
cf
review
collaco
cut
lead
candid
includ
inflammatori
mediat
cytokin
recent
well
gene
polymorph
affect
respons
bacteri
infect
betadefensin
ancestr
mhc
haplotyp
diseas
cf
mani
factor
influenc
cours
diseas
differ
clinic
paramet
take
account
lung
function
bacteri
burden
inflamm
identif
signific
modifi
gene
requir
larg
popul
studi
ultim
could
provid
new
target
antiinflammatori
drug
gene
silenc
rnai
strategi
amelior
diseas
inde
like
gene
silenc
therapi
includ
shrna
pdna
construct
evalu
directli
base
modifi
gene
gener
pathophysiolog
cf
exampl
reduct
transcript
factor
nuclear
factor
kappa
b
regul
mani
proinflammatori
cytokin
play
central
role
exagger
innat
immun
respons
cf
ermembran
protein
involv
block
misfold
cftr
may
benefici
improv
nonvir
gene
transfer
gene
silenc
may
becom
realist
treatment
option
singl
novel
therapeut
approach
cf
treatment
yet
shown
suffici
promis
stand
field
howev
understand
molecular
process
cf
lung
deepen
better
preclin
model
evalu
becom
clearer
earli
broad
intervent
necessari
prevent
multifacet
defect
accompani
cftr
mutat
pharmacolog
approach
head
clinic
trial
regular
pace
preclin
studi
show
correct
sever
major
defect
although
challeng
find
safe
effect
formul
permit
slow
progress
gene
therapi
still
provid
great
opportun
allround
therapeut
intervent
